Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 201–300 of 15,747
Gluckman, T. J., Bhave, N. M., Allen, L. A., Chung, E. H., Spatz, E. S., Ammirati, E., Baggish, A. L., Bozkurt, B., Cornwell, W. K., Harmon, K. G., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.003 · Cited by 389
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2202542 · Cited by 386
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Self-citationCOVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
Ella, R., Reddy, S., Jogdand, H., Sarangi, V., Ganneru, B., Prasad, S., Das, D., Raju, D., Praturi, U., Sapkal, G., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00070-0 · Cited by 378
Covid‐19 vaccines and variants of concern: A review
Hadj Hassine, I. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2313 · Cited by 383
“The preliminary data from phase 2/3 clinical trials demonstrated that BNT162b2 had 95% efficacy in preventing symptomatic SARS‐CoV‐2 infections.(62) The quick spread of UK and South Africa variants (both encoding”
BackgroundMethodInfluentialBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03693-y · Cited by 342
Self-citationTrials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
“…have shown to deliver on their promise, i.e., they can be developed extremely quickly, can be manufactured under GMP-compliant manufacturing processes, and can be scaled for rapid availability of large numbers of doses, are safe and are active at a relatively low dose range [140,225,286,287].”
BackgroundEffect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378
COVID-19 and Cardiovascular Disease: From Bench to Bedside
Chung, M. K., Zidar, D. A., Bristow, M. R., Cameron, S. J., Chan, T., Harding, C. V., Kwon, D. H., Singh, T., Tilton, J. C., Tsai, E. J., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.317997 · Cited by 373
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373
Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., Zaccardi, F., Watkinson, P., Shankar-Hari, M., Doidge, J., et al. (2021) · BMJ · doi:10.1136/bmj.n1931 · Cited by 371
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
“Both Moderna and Pfizer modified the mRNA encoding viral spike protein by replacing natural residues with two consecutive prolines at amino acid positions K986 and V987 for their COVID-19 vaccines [5,6,8].”
BackgroundInfluentialAntibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367
Self-citationSymptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Marshall, M., Ferguson, I. D., Lewis, P., Jaggi, P., Gagliardo, C., Collins, J. S., Shaughnessy, R., Caron, R., Fuss, C., Corbin, K. J. E., et al. (2021) · Pediatrics · doi:10.1542/peds.2021-052478 · Cited by 367
Heinz, F. X., & Stiasny, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00369-6 · Cited by 363
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 363
Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., Naffaa, M. E., et al. (2021) · Vaccines · doi:10.3390/vaccines9050435 · Cited by 363
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England
Harris, R. J., Hall, J. A., Zaidi, A., Andrews, N. J., Dunbar, J. K., & Dabrera, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107717 · Cited by 355
“The data were processed lawfully under General Data Protection Regulation Article 6(1)e and 9(2)i and shared under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002.”
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Falsey, A. R., Frenck, R. W., Walsh, E. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Bailey, R., Swanson, K. A., Xu, X., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113468 · Cited by 361
Self-citationReactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines
Chapin-Bardales, J., Gee, J., & Myers, T. (2021) · JAMA · doi:10.1001/jama.2021.5374 · Cited by 359
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00345-0 · Cited by 360
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359
Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01420-3 · Cited by 350
Geisen, U. M., Berner, D. K., Tran, F., Sümbül, M., Vullriede, L., Ciripoi, M., Reid, H. M., Schaffarzyk, A., Longardt, A. C., Franzenburg, J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220272 · Cited by 355
Grupper, A., Rabinowich, L., Schwartz, D., Schwartz, I. F., Ben-Yehoyada, M., Shashar, M., Katchman, E., Halperin, T., Turner, D., Goykhman, Y., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16615 · Cited by 355
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 351
Stone, C. A., Liu, Y., Relling, M. V., Krantz, M. S., Pratt, A. L., Abreo, A., Hemler, J. A., & Phillips, E. J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.12.003 · Cited by 351
Seroconversion rates following COVID-19 vaccination among patients with cancer
Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.002 · Cited by 344
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Steensels, D., Pierlet, N., Penders, J., Mesotten, D., & Heylen, L. (2021) · JAMA · doi:10.1001/jama.2021.15125 · Cited by 351
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“mRNA-1273 vaccine candidates, both encoding the SARS-CoV-2 pre-fusion stabilized S2P protein, which showed very high efficacy in Phase 3 trials (Baden et al., 2020a; Jackson et al., 2020; Mulligan et al., 2020; Polack et al., 2020).”
Vuong, Q.-H., Le, T.-T., La, V.-P., Nguyen, H. T. T., Ho, M.-T., Van Khuc, Q., & Nguyen, M.-H. (2022) · Humanities and Social Sciences Communications · doi:10.1057/s41599-022-01034-6 · Cited by 344
Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 342
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00220-4 · Cited by 342
Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M. H., Turner, D. L., & Turner, R. J. (2021) · Vaccines · doi:10.3390/vaccines9050467 · Cited by 339
COVID-19 in early 2021: current status and looking forward
Wang, C., Wang, Z., Wang, G., Lau, J. Y.-N., Zhang, K., & Li, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00527-1 · Cited by 339
Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study
Mizrahi, B., Sudry, T., Flaks-Manov, N., Yehezkelli, Y., Kalkstein, N., Akiva, P., Ekka-Zohar, A., Ben David, S. S., Lerner, U., Bivas-Benita, M., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072529 · Cited by 335
Achiron, A., Mandel, M., Dreyer-Alster, S., Harari, G., Magalashvili, D., Sonis, P., Dolev, M., Menascu, S., Flechter, S., Falb, R., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211012835 · Cited by 333
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., Fontana, M., Smit, A., Sackville-West, J. E., Cutino-Moguel, T., et al. (2021) · Science · doi:10.1126/science.abh1282 · Cited by 338
Self-citationSARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y., & Balicer, R. D. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00662-4 · Cited by 336
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S., Sunny, S.-K., Moore, Z., & Zeng, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117128 · Cited by 333
Chia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J.-M., Mak, T.-M., Cui, L., Kalimuddin, S., Chia, W. N., Tan, C. W., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.010 · Cited by 331
Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons
Kissler, S. M., Fauver, J. R., Mack, C., Tai, C. G., Breban, M. I., Watkins, A. E., Samant, R. M., Anderson, D. J., Metti, J., Khullar, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102507 · Cited by 335
Wei, J., Stoesser, N., Matthews, P. C., Ayoubkhani, D., Studley, R., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00947-3 · Cited by 331
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 331
Brosh-Nissimov, T., Orenbuch-Harroch, E., Chowers, M., Elbaz, M., Nesher, L., Stein, M., Maor, Y., Cohen, R., Hussein, K., Weinberger, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.036 · Cited by 327
“The mRNA coronavirus disease 2019 (COVID-19) vaccines, Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273, were 94%e95% effective in preventing symptomatic COVID-19 in phase III studies, showing similar efficacy in different age groups, including persons older than 75 years, and persons with comorbidities [1,2].”
Muramatsu, H., Lam, K., Bajusz, C., Laczkó, D., Karikó, K., Schreiner, P., Martin, A., Lutwyche, P., Heyes, J., & Pardi, N. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.001 · Cited by 331
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Moreira, E. D., Kitchin, N., Xu, X., Dychter, S. S., Lockhart, S., Gurtman, A., Perez, J. L., Zerbini, C., Dever, M. E., Jennings, T. W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200674 · Cited by 328
Self-citationNeutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
Yu, J., Collier, A.-R. Y., Rowe, M., Mardas, F., Ventura, J. D., Wan, H., Miller, J., Powers, O., Chung, B., Siamatu, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201849 · Cited by 326
Nanoparticles in the clinic: An update post COVID‐19 vaccines
Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10246 · Cited by 337
“Collectively, mRNA-1273 and BNT162b2 are used in >35 countries10 with an estimated 3 billion (2 billion for BNT162b2 and 1 billion for mRNA-1273) doses to be manufactured throughout 2021.18 Table 1 has been updated to list FDA/EMA approved injectable nanomedicines up to 2021, including the lipid nanoparticle mRNA vacc…”
BackgroundInfluentialMateus, J., Dan, J. M., Zhang, Z., Moderbacher, C. R., Lammers, M., Goodwin, B., Sette, A., Crotty, S., & Weiskopf, D. (2021) · doi:10.1101/2021.06.30.21259787 · Cited by 327
“=33) and COVID-19 convalescent donors at 170-195 days PSO 10 (yellow circles, n=14).”
BackgroundInfluentialLow-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
(2021) · doi:10.1126/science.abj9853 · Cited by 327
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
Grupper, A., Sharon, N., Finn, T., Cohen, R., Israel, M., Agbaria, A., Rechavi, Y., Schwartz, I. F., Schwartz, D., Lellouch, Y., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03500321 · Cited by 318
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01410-w · Cited by 326
Menni, C., May, A., Polidori, L., Louca, P., Wolf, J., Capdevila, J., Hu, C., Ourselin, S., Steves, C. J., Valdes, A. M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00146-3 · Cited by 323
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.10.011 · Cited by 322
“Although Pfizer’s clinical trial described an efficacy of 52% against symptomatic infection after a single dose (Polack et al., 2020), the United Kingdom’s Joint Committee on Vaccination and Immunisation (JCVI) estimated an efficacy of 89% against symptomatic infection, having removed infection…”
BackgroundSelf-citationmRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321
“Both mRNA vaccines have been found to be highly effective and safe in preventing COVID-19 according to clinical trials [4, 5].”
BackgroundLow immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
Rabinowich, L., Grupper, A., Baruch, R., Ben-Yehoyada, M., Halperin, T., Turner, D., Katchman, E., Levi, S., Houri, I., Lubezky, N., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.020 · Cited by 320
“Introduction Two novel mRNA technology-based SARS-CoV-2 vaccines, developed by Pfizer and Moderna, are currently approved, with efficacy reaching 94–95% in clinical trials.(1,2) Solid organ transplant (SOT) recipients were excluded from those trials, thus, the vaccine’s immunogenicity in this population is unknown.”
BackgroundMacrophage Polarity and Disease Control
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010144 · Cited by 318
“The quick development of a vaccine could prove highly effective and, with widespread use, could bring this infection under control [49,50].”
BackgroundScalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
Shepherd, S. J., Warzecha, C. C., Yadavali, S., El-Mayta, R., Alameh, M.-G., Wang, L., Weissman, D., Wilson, J. M., Issadore, D., & Mitchell, M. J. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01353 · Cited by 317
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu-Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01464-w · Cited by 340
Watanabe, A., Iwagami, M., Yasuhara, J., Takagi, H., & Kuno, T. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.008 · Cited by 304
“However, it should be noted that an online survey showed that the majority of the reported symptoms that worsened following vaccination were those commonly observed in the general population, such as fever, chills, and gastrointestinal symptoms [13], while the symptomatic improvement following vaccination was mainly d…”
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Mudd, P. A., Minervina, A. A., Pogorelyy, M. V., Turner, J. S., Kim, W., Kalaidina, E., Petersen, J., Schmitz, A. J., Lei, T., Haile, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.026 · Cited by 309
“COVID-19 mRNA vaccines exhibit the highest efficacy in phase 3 studies among widely utilized COVID-19 vaccines worldwide (Al Kaabi et al., 2021; Baden et al., 2021; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021).”
InfluentialBNT162b2 Vaccine Booster and Mortality Due to Covid-19
Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2115624 · Cited by 309
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310
Hippisley-Cox, J., Coupland, C. A., Mehta, N., Keogh, R. H., Diaz-Ordaz, K., Khunti, K., Lyons, R. A., Kee, F., Sheikh, A., Rahman, S., et al. (2021) · BMJ · doi:10.1136/bmj.n2244 · Cited by 308
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
“In the BNT162b2 phase II/III trial, with a total of 43,548 participants 16 years of age or older, two doses of BNT162b2 resulted in confirmation of the favorable safety profile and 95% vaccine efficacy (prevention of COVID-19).(8) In 12- to 15-year-olds, two 30 mg doses of BNT162b2 showed a favorable safety profile an…”
InfluentialPrimary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Bates, T. A., McBride, S. K., Leier, H. C., Guzman, G., Lyski, Z. L., Schoen, D., Winders, B., Lee, J.-Y., Lee, D. X., Messer, W. B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8014 · Cited by 302
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00448-7 · Cited by 306
Nordström, P., Ballin, M., & Nordström, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00089-7 · Cited by 302
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Stephenson, K. E., Le Gars, M., Sadoff, J., de Groot, A. M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., et al. (2021) · JAMA · doi:10.1001/jama.2021.3645 · Cited by 302
Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses
Cortés, H., Hernández-Parra, H., Bernal-Chávez, S. A., Prado-Audelo, M. L. D., Caballero-Florán, I. H., Borbolla-Jiménez, F. V., González-Torres, M., Magaña, J. J., & Leyva-Gómez, G. (2021) · Materials · doi:10.3390/ma14123197 · Cited by 302
“Recently, BioNTech and Pfizer used two novel surfactants in the formulation of their BNT162b2 mRNA Covid-19 vaccine, the PEG-ylated lipid ALC0159 (2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide) and the cationic lipid ALC-0315 ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)) [48,49].”
MethodWang, Q., Yang, L., Jin, H., & Lin, L. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106694 · Cited by 299
“The efficacy of the BNT162b2 mRNA vaccine has been reported to be 95% (Polack et al., 2020), that of the mRNA-1273 vaccine is 94.1% (Baden et al., 2021), that of the Gam-COVID-Vac (Sputnik V) is 91.6% (Logunov et al., 2021), and that of the ChAdOx1 nCoV-19 vaccine is 70.4% (Voysey et al., 2021).”
InfluentialTenforde, M. W., Olson, S. M., Self, W. H., Talbot, H. K., Lindsell, C. J., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Douin, D. J., Prekker, M. E., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018e1 · Cited by 294
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
(2021) · doi:10.1038/s41467-021-24285-4 · Cited by 272
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Mendonça, S. A., Lorincz, R., Boucher, P., & Curiel, D. T. (2021) · npj Vaccines · doi:10.1038/s41541-021-00356-x · Cited by 294
Suzuki, Y., & Ishihara, H. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100424 · Cited by 298
“These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. lable at ScienceDirect Drug Metabolism and Pharmacokinetics 41 (2021) 100424 Contents lists avai Drug Metabolism and Pharmacokinetics journal homepage: http: / /www.journals.e lsevier .com/drug-metabol ism-an…”
InfluentialWillingness to Receive COVID-19 Vaccination in Japan
Yoda, T., & Katsuyama, H. (2021) · Vaccines · doi:10.3390/vaccines9010048 · Cited by 292
De, R., Mahata, M. K., & Kim, K. (2022) · Advanced Science · doi:10.1002/advs.202105373 · Cited by 297
Stumpf, J., Siepmann, T., Lindner, T., Karger, C., Schwöbel, J., Anders, L., Faulhaber-Walter, R., Schewe, J., Martin, H., Schirutschke, H., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100178 · Cited by 291
“mRNA vaccines as used in this study cohort appeared safe in all groups similar to the phase 3 clinical trials for BNT162b2 [31] and mRNA-1273 [32].”
MethodWu, S., Huang, J., Zhang, Z., Wu, J., Zhang, J., Hu, H., Zhu, T., Zhang, J., Luo, L., Fan, P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00396-0 · Cited by 290
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K., Lu, X., Parks, R., Sutherland, L. L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.021 · Cited by 287
Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
Goldshtein, I., Nevo, D., Steinberg, D. M., Rotem, R. S., Gorfine, M., Chodick, G., & Segal, Y. (2021) · JAMA · doi:10.1001/jama.2021.11035 · Cited by 288
Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis
Ng, W. H., Tipih, T., Makoah, N. A., Vermeulen, J.-G., Goedhals, D., Sempa, J. B., Burt, F. J., Taylor, A., & Mahalingam, S. (2021) · mBio · doi:10.1128/mbio.03647-20 · Cited by 288
Emerging non-viral vectors for gene delivery
Wang, C., Pan, C., Yong, H., Wang, F., Bo, T., Zhao, Y., Ma, B., He, W., & Li, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02044-5 · Cited by 286
“Both vaccines in clinical phase II showed highly protective efficiency (> 94%) [103].”
BackgroundAn Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288
Kadali, R. A. K., Janagama, R., Peruru, S., & Malayala, S. V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.047 · Cited by 285
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · Science · doi:10.1126/science.abj0299 · Cited by 286
Prasad, S., Kalafat, E., Blakeway, H., Townsend, R., O’Brien, P., Morris, E., Draycott, T., Thangaratinam, S., Le Doare, K., Ladhani, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30052-w · Cited by 280
SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women
Perl, S. H., Uzan-Yulzari, A., Klainer, H., Asiskovich, L., Youngster, M., Rinott, E., & Youngster, I. (2021) · JAMA · doi:10.1001/jama.2021.5782 · Cited by 285
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 285
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.